糖类抗原19-9在评估晚期胰腺癌化疗反应中的应用
CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer.
作者信息
Ishii H, Okada S, Sato T, Wakasugi H, Saisho H, Furuse J, Ishikawa O, Matsuno S, Yokoyama S
机构信息
Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.
出版信息
Hepatogastroenterology. 1997 Jan-Feb;44(13):279-83.
BACKGROUND/AIMS: The determination of serum carbohydrate antigen 19-9 (CA 19-9) level is useful in managing pancreatic cancer. However, the usefulness of this marker in evaluating the response to chemotherapy has not been fully established.
MATERIALS AND METHODS
Serial changes of serum CA 19-9 levels were studied during chemotherapy in 66 pancreatic cancer patients who showed CA 19-9 level of 100 U/ml or greater before treatment. We investigated the relationship between patient survival and reduction in serum CA 19-9 level after treatment.
RESULTS
When a responder was defined as a patient whose serum CA 19-9 level was reduced by more than 50% of the pre-treatment level within 2 months after treatment, CA 19-9 response was observed in 9 (13%) of the 66 patients. Median survival times of CA 19-9 responders and non-responders were 141 and 88 days, respectively. Based on Cox regression analysis, the relative risk of cancer death in CA 19-9 responders for non-responders was 0.47 (95% confidence interval, 0.21 to 1.05).
CONCLUSIONS
CA 19-9 reduction may be useful for assessing the efficacy of chemotherapy for advanced pancreatic cancer.
背景/目的：血清糖类抗原19-9（CA 19-9）水平的测定对胰腺癌的治疗有帮助。然而，该标志物在评估化疗反应中的作用尚未完全确立。
材料与方法
对66例治疗前血清CA 19-9水平≥100 U/ml的胰腺癌患者化疗期间血清CA 19-9水平的系列变化进行研究。我们调查了患者生存与治疗后血清CA 19-9水平降低之间的关系。
结果
若将治疗后2个月内血清CA 19-9水平降低超过治疗前水平50%的患者定义为反应者，则66例患者中有9例（13%）出现CA 19-9反应。CA 19-9反应者和无反应者的中位生存时间分别为141天和88天。基于Cox回归分析，CA 19-9反应者相对于无反应者癌症死亡的相对风险为0.47（95%置信区间，0.21至1.05）。
结论
CA 19-9水平降低可能有助于评估晚期胰腺癌化疗的疗效。
Zotero 插件